Skip to main content
SpringerLink
Log in

The Management of HIV-Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1083 Accesses

Abstract

Since 1996, the availability of highly active antiretroviral therapy (HAART) has led to improvements in immune status among HIV-infected persons, reducing AIDS-related morbidity and prolonging survival. However, despite the impact of HAART on HIV-related mortality, malignancies remain an important cause of death in the current era (Clin Infect Dis 48(5):633–639, 2009; Clin Infect Dis 49(3):481–482, 2009). The use of HAART was also associated with reduced incidence of the two major AIDS-associated malignancies – Kaposi’s sarcoma (KS) and high-grade non-Hodgkin lymphoma (NHL) (AIDS 20:1645–1654, 2006). However, among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma (HL), anal cancer, lung cancer, and hepatocarcinoma has been observed recently (Blood 108:3786–3791, 2006).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis. 2009;48(5):633–9.

    Article  PubMed  Google Scholar 

  2. Serraino D, Dal Maso L, De Paoli A, et al. On changes in cancer mortality among HIV-infected patients: is there an excess risk of death from pancreatic cancer? Clin Infect Dis. 2009;49(3):481–2.

    Article  PubMed  Google Scholar 

  3. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645–54.

    Article  PubMed  Google Scholar 

  4. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108:3786–91.

    Article  PubMed  CAS  Google Scholar 

  5. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60:1365–72.

    Article  PubMed  CAS  Google Scholar 

  6. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin’s disease and human immmunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13:1758–67.

    PubMed  CAS  Google Scholar 

  7. Curado M P, Edwards B, Shin HR, et al., editors. Cancer incidence in five continents, Vol. IX IARC Scientific Publications No. 160. Lyon: IARC; 2007.

    Google Scholar 

  8. Hjalgrim H, Askling J, Pukkala E, et al. Incidence of Hodgkin’s disease in Nordic countries. Lancet. 2001;358:297–8.

    Article  PubMed  CAS  Google Scholar 

  9. Biggar RJ, Horm J, Goedert JJ, et al. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol. 1987;126:578–86.

    PubMed  CAS  Google Scholar 

  10. Hessol NA, Katz MH, Liu JY, et al. Increased incidence of Hodgkin disease in homosexual men with HIV infection. Ann Intern Med. 1992;117:309–11.

    PubMed  CAS  Google Scholar 

  11. Serraino D, Carbone A, Franceschi S, et al. Increased frequency of lymphocyte depletion and mixed cellularity subtypes of Hodgkin disease in HIV-infected patients. Italian Cooperative Group on AIDS and Tumours. Eur J Cancer. 1993;29A:1948–50.

    Article  PubMed  CAS  Google Scholar 

  12. Serraino D, Pezzotti P, Dorrucci M, et al. Cancer incidence in a cohort of human immunodeficiency virus seroconveters. HIV Italian Seroconverters Study Group. Cancer. 1997;79:1004–8.

    Article  PubMed  CAS  Google Scholar 

  13. Franceschi S, Dal Maso L, Arniani D, et al. Risk of cancer other than Kaposi sarcoma and non-Hodgkin’s lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer. 1998;78:966–70.

    Article  PubMed  CAS  Google Scholar 

  14. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823–30.

    Article  Google Scholar 

  15. Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002;16:1155–61.

    Article  PubMed  Google Scholar 

  16. Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985–1998. Br J Cancer. 2003;89:94–100.

    Article  PubMed  CAS  Google Scholar 

  17. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003;21:3447–53.

    Article  PubMed  Google Scholar 

  18. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–32.

    Article  PubMed  Google Scholar 

  19. Serraino D, Piselli P, Busnach G, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 2007;43:2117–23.

    Article  PubMed  Google Scholar 

  20. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187–94.

    Article  PubMed  CAS  Google Scholar 

  21. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27(6):884–90.

    Article  PubMed  Google Scholar 

  22. Levine AM. Hodgkin lymphoma: to the HAART of the matter. Blood. 2006;108:3630.

    Article  CAS  Google Scholar 

  23. Gloghini A, Carbone A. Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? Int J Cancer. 2007;120:2753–4.

    Article  PubMed  CAS  Google Scholar 

  24. Carbone A, Cabras A, Gloghini A. HIV-associated Hodgkin’s lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity. Int J Biol Markers. 2007;22:161–3.

    PubMed  CAS  Google Scholar 

  25. Dolcetti R, Boiocchi M, Gloghini A, Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin’s disease. Eur J Cancer. 2001;37(10):1276–87.

    Article  PubMed  CAS  Google Scholar 

  26. Said JW. Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol. 2007;14:189–94.

    Article  PubMed  Google Scholar 

  27. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus associated Hodgkin’s disease derives from post-germinal center B cells. Blood. 1999;93:2319–26.

    PubMed  CAS  Google Scholar 

  28. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007;38:1293–304.

    Article  PubMed  CAS  Google Scholar 

  29. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist. 2008;13:577–85.

    Article  PubMed  Google Scholar 

  30. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8:22–33.

    Article  PubMed  CAS  Google Scholar 

  31. Vockerodt M, Morgan S, Kuo M, et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin’s Reed-Sternberg-like phenotype. J Pathol. 2008;216(1):83–92.

    Article  PubMed  CAS  Google Scholar 

  32. Tirelli U, Vaccher E, Serraino D, et al. Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML). Haematologica. 1987;72:563–5.

    PubMed  CAS  Google Scholar 

  33. Andrieu JM, Roithmann S, Tourani JM, et al. Hodgkin’s disease during HIV-1 infection: the French registry experience. Ann Oncol. 1993;4:635–41.

    PubMed  CAS  Google Scholar 

  34. Rubio R. disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cancer. 1994;73:2400–7.

    Article  PubMed  CAS  Google Scholar 

  35. Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodefiency virus-related NHL in the era of HAART. Clin Infect Dis. 2003;37:1556–64.

    Article  PubMed  Google Scholar 

  36. Chimienti E, Spina M, Gastaldi R, et al. Clinical characteristics and outcome of 290 patients (pts) with Hodgkin’s disease and HIV infection (HD-HIV) in pre and HAART (highly active antiretroviral therapy) era. Ann Oncol 2008;19:iv136, abstract 168.

    Google Scholar 

  37. Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS related Hodgkin Lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:422–8.

    Article  PubMed  CAS  Google Scholar 

  38. Errante D, Tirelli U, Gastaldi R, et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin’s disease and human immunodeficiency virus infection. A prospective study of 17 patients. Cancer. 1994;73:437–44.

    Article  PubMed  CAS  Google Scholar 

  39. Errante D, Gabarre J, Ridolfo AL, et al. Hodgkin’s disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol. 1999;10:189–95.

    Article  PubMed  CAS  Google Scholar 

  40. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine and dacarbazine with granulocyte-colony-stimulating factor CSF in HIV infected patients with newly diagnosed Hodgkin’s disease: a prospective, multi-institutional AIDS Clinical Trials Group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24:444–50.

    PubMed  CAS  Google Scholar 

  41. Gastaldi R, Martino P, Gentile G, et al. Hodgkin’s disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor. Ann Oncol. 2002;13(7):1158–60.

    Article  PubMed  CAS  Google Scholar 

  42. Spina M, Gabarre J, Rossi G, et al. Stanford V and concomitant HAART in 59 patients with Hodgkin’s disease and HIV infection. Blood. 2002;100:1984–8.

    Article  PubMed  CAS  Google Scholar 

  43. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol. 2003;14:1562–9.

    Article  PubMed  CAS  Google Scholar 

  44. Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage human immunodefiency virus-related Hodgkin’s lymphoma. Haematologica. 2007;92:191–8.

    Article  PubMed  CAS  Google Scholar 

  45. Xicoy B, Ribera JM, Romeu J, et al. Response to highly active antiretroviral therapy as the only therapy in an HIV-infected patient with interfollicular Hodgkin’s lymphoma. Haematologica. 2007;92:191–8.

    Article  PubMed  CAS  Google Scholar 

  46. Spina M, Rossi G, Antinori A, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV). Ann Oncol 2008;19:iv152, abstract 227.

    Google Scholar 

  47. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency (HIV)-related lymphoma: results and impact on HIV disease. Haematologica. 2004;89:1100–8.

    PubMed  Google Scholar 

  48. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003;21:4423–7.

    Article  PubMed  CAS  Google Scholar 

  49. Krishnan A, Molina A, Zaia J, et al. Durable remission with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105:874–8.

    Article  PubMed  CAS  Google Scholar 

  50. Serrano D, Carrion R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005;33:487–94.

    Article  PubMed  CAS  Google Scholar 

  51. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306–13.

    Article  PubMed  CAS  Google Scholar 

  52. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced Busulfan, Cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium Study 020. Biol Blood Marrow Transpl. 2008;14:59–66.

    Article  CAS  Google Scholar 

  53. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.

    Article  PubMed  Google Scholar 

  54. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.

    Article  PubMed  Google Scholar 

  55. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91(4):475–81.

    PubMed  Google Scholar 

  56. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52–9.

    Article  PubMed  CAS  Google Scholar 

  57. Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin’s disease: potential for a prognostic factor. Cancer Res. 2005;65(13):5516–9.

    Article  PubMed  CAS  Google Scholar 

  58. Just PA, Fieschi C, Baillet G, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDs. 2008;22(9):695–700.

    Article  PubMed  Google Scholar 

  59. Goshen E, Davidson T, Avigdor A, et al. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med. 2008;33(9):610–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology A, National Cancer Institute, Via Franco Gallini 2, 33081, Aviano, PN, Italy

    Michele Spina & Umberto Tirelli

Authors
  1. Michele Spina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Umberto Tirelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michele Spina .

Editor information

Editors and Affiliations

  1. Klinik I für Innere Medizin, Universität Köln, Joseph-Stelzmann-Str. 9, Köln, 50924, Germany

    Andreas Engert

  2. Dept. Medicine, Stanford University, Stanford, 94305-5479, California, USA

    Sandra J. Horning

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Spina, M., Tirelli, U. (2011). The Management of HIV-Hodgkin Lymphoma. In: Engert, A., Horning, S. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12780-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12780-9_17

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12779-3

  • Online ISBN: 978-3-642-12780-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation